United Therapeutics Corporation (NASDAQ:UTHR) Q3 2025 Earnings Call Transcript
United Therapeutics Corporation (NASDAQ:UTHR) Q3 2025 Earnings Call Transcript October 29, 2025United Therapeutics Corporation beats earnings expectations.
United Therapeutics Corp (UTHR)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Polaris Capital Management Bernard Horn | 122,050 | $51,164,581 | -5% | 3.36% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $82.83 | 4 | $331.32 | 1,684 | 2019-06-10 | Filing | |
| $114.06 | 6 | $684.36 | 1,686 | 2018-04-20 | Filing | |
| $126.20 | 5 | $631.00 | 1,685 | 2017-11-20 | Filing | |
| $128.35 | 3 | $385.05 | 1,686 | 2017-07-28 | Filing | |
| $130.24 | 3 | $390.72 | 1,683 | 2017-07-17 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $452.21 | 1,180 | $533,607.80 | 130 | 2025-11-07 | Filing | |
| $448.04 | 300 | $134,412.00 | 1,310 | 2025-11-07 | Filing | |
| $446.42 | 2,520 | $1,124,988.23 | 1,610 | 2025-11-07 | Filing | |
| $449.44 | 1,345 | $604,499.62 | 130 | 2025-11-06 | Filing | |
| $448.14 | 2,655 | $1,189,808.25 | 1,475 | 2025-11-06 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 4,418,610 | $1,852,325,498 | 0.03% | |
| 2. | 645,908 | $270,771,197 | 0.58% | |
| 3. | 351,455 | $147,333,387 | 0.03% | |
| 4. | 339,071 | $142,141,954 | 0.36% | |
| 5. | 329,118 | $137,969,558 | 0.14% |
News See All
Jefferies Reiterates Buy Rating on United Therapeutics (UTHR) Amid Patent Case
United Therapeutics Corporation (NASDAQ:UTHR) is one of the best stocks to buy according to Jim Simons’ Renaissance Technologies.
11 Best Stocks to Buy According to Jim Simons’ Renaissance Technologies
Renaissance Technologies has not had the best of runs in an action-filled year that has seen equity markets rally to record highs.
H.C. Wainwright Lowers PT on United Therapeutics Corporation (UTHR) to $400 From $425, Keeps a Buy Rating
United Therapeutics Corporation (NASDAQ:UTHR) is one of the top cheap pharmaceutical stocks to buy now. H.C.
11 Cheap Pharmaceutical Stocks to Buy Now
The White House announced on Thursday that President Trump sent 17 major pharmaceutical companies letters delineating the steps they should take to decrease the prices of US prescription drugs to “most...
United Therapeutics Corporation (NASDAQ:UTHR) Q2 2025 Earnings Call Transcript
United Therapeutics Corporation (NASDAQ:UTHR) Q2 2025 Earnings Call Transcript July 30, 2025United Therapeutics Corporation misses on earnings expectations.
BTIG Lowers Liquidia (LQDA) PT to $40, Potential for Yutrepia Launch Remains a Focus
Liquidia Corporation (NASDAQ:LQDA) is one of the biotech stocks to buy according to Wall Street analysts.
Leerink Partners Remains a Buy on United Therapeutics Corporation (UTHR) With a $408 PT
United Therapeutics Corporation (NASDAQ:UTHR) is one of the most profitable biotech stocks to invest in now.
United Therapeutics Corporation (UTHR) Launches First UKidney Human Trial
We recently compiled a list of 10 Most Undervalued Healthcare Stocks to Buy According to Analysts.
10 Most Profitable Biotech Stocks to Invest in Now
Jared Holz, Mizuho health care equity strategist, appeared on CNBC’s 'Power Lunch' on March 5 to talk about investing in biotech and the oversaturation in the sector.
Hedge Fund Resource Center Billionaire Hedge Funds
